EUVIMEDEUVIMED entdecken
Crossref

The future of early endpoints for neoadjuvant therapy

Christina Yau, Laura J Esserman

Cancer Cell · 2026-11

DOI: 10.1016/j.ccell.2026.10.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2026-11. Verfasst von Christina Yau und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of California San Francisco, San Francisco, CA, USA. Die Arbeit nennt 10 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Early endpoints as surrogates for long-term outcomes are essential for treatment efficacy evaluation. In this issue of Cancer Cell, Conforti et al. report that CPS + EG and Neo-Bioscore scores predict long-term outcomes at the patient level but not at the trial level, highlighting the need for better early endpoints that reliably capture efficacy across trials.

Autor:innen und Institutionen

  • Department of Surgery, University of California San Francisco, San Francisco, CA, USA.
  • Department of Surgery, University of California San Francisco, San Francisco, CA, USA. Electronic address: laura.esserman@ucsf.edu.

Zitieren

APA

Yau, C., & Esserman, L. J. (2026). The future of early endpoints for neoadjuvant therapy. Cancer Cell. https://doi.org/10.1016/j.ccell.2026.10.010

Vancouver

Yau C, Esserman LJ. The future of early endpoints for neoadjuvant therapy. Cancer Cell. 2026. doi:10.1016/j.ccell.2026.10.010

BibTeX
@article{Yau2026,
  author = {Yau, Christina and Esserman, Laura J},
  title = {The future of early endpoints for neoadjuvant therapy},
  journal = {Cancer Cell},
  year = {2026},
  doi = {10.1016/j.ccell.2026.10.010}
}
Kostenlos starten →